Effects of a single oral dose of cilostazol on epicardial coronary arteries and hemodynamics in humans

Circulation Journal : Official Journal of the Japanese Circulation Society
Masahiro YasutakeHirokazu Hayakawa

Abstract

Cilostazol, a novel cyclic adenosine monophosphate phosphodiesterase type III inhibitor, has been developed as an antiplatelet drug with a vasodilating action on peripheral arteries. The present study was designed to test, in humans, whether cilostazol can dilate the epicardial coronary arteries and what are its hemodynamic effects. Eight patients with chest pain syndrome were subjected to serial quantitative coronary arteriography immediately before and at 30, 60 and 150min after a single oral dose of cilostazol (200mg). Luminal cross-sectional areas (mm2) at the proximal and distal sites of major coronary arteries (6 segments at each sampling time) were significantly increased at 150 min after taking the drug. The percent increases relative to the baseline values were 25+/-7 (6.8+/-0.8-->8.3+/-1.0*) and 42+/-7% (2.1+/-0.3-->3.0+/-0.4*) in the right coronary artery, 24+/-5 (5.1+/-0.7-->6.1+/-0.8*) and 28+/-10% (1.6+/-0.31-->9+/-0.3*) in the left anterior descending artery, and 14+/-6 (5.9+/-0.9-->6.6+/-0.9*) and 24+/-10% (1.3+/-0.2-->1.5+/-0.2*) in the left circumflex artery, respectively (*p<0.05 vs baseline). This action, relative to that of nitroglycerine, was between 27% and 54%. Moreover, small but sustained decreases in ...Continue Reading

References

Oct 14, 1988·Biochemical and Biophysical Research Communications·C MaziereJ Polonovski
Sep 1, 1987·Catheterization and Cardiovascular Diagnosis·K H SilverA B Nichols
Jan 1, 1995·American Journal of Respiratory and Critical Care Medicine·M FujimuraT Matsuda
Jun 1, 1997·The American Journal of Cardiology·M OchiaiH Miyashita
Apr 29, 1998·Journal of Clinical Pharmacology·A SuriS L Bramer
Apr 29, 1998·Journal of Cardiovascular Pharmacology·H AtarashiH Hayakawa
Dec 22, 1999·The American Journal of Cardiology·Y YoonS Y Cho
Sep 29, 2000·The American Journal of Cardiology·S W ParkS J Park
Nov 7, 2000·The American Journal of Medicine·D L DawsonD E Strandness
Jan 11, 2001·Journal of Cardiovascular Pharmacology and Therapeutics·S ToyonagaT Tsuji

❮ Previous
Next ❯

Citations

Jul 1, 2004·Circulation Journal : Official Journal of the Japanese Circulation Society·Makoto SekiguchiMasahiko Kurabayashi
Nov 11, 2009·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Shinichiro UchiyamaSun Uck Kwon
Oct 2, 2007·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Sebastián F AmerisoAntonio Ricardo La Mura
Sep 20, 2005·American Heart Journal·Yaling HanJunbo Ge
Oct 22, 2021·Journal of Clinical Pharmacology·Antonis A ManolisAntonis S Manolis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.